Stockscreener 앱 받기
10.97
6.24%
-0.73
시간 외 거래:
11.08
0.11
+1.00%
전일 마감가:
$11.70
열려 있는:
$11.78
하루 거래량:
1.83M
Relative Volume:
1.05
시가총액:
$784.79M
수익:
-
순이익/손실:
$-34.98M
주가수익비율:
-11.93
EPS:
-0.9199
순현금흐름:
$-32.77M
1주 성능:
-12.24%
1개월 성능:
-24.19%
6개월 성능:
+23.12%
1년 성능:
+437.75%
1일 변동 폭
$10.82
$11.99
1주일 범위
$10.82
$12.90
52주 변동 폭
$1.99
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.97 | 784.79M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | Morgan Stanley | Overweight |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2026-02-09 | 개시 | Mizuho | Outperform |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Global BMI Index - marketscreener.com
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion - Investing.com
Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating - Yahoo Finance
IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead - TradingView
IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval - TradingView
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
IMMX Q2 2026 Earnings: Modest EPS Miss Signals Continued Clinical-Stage InvestmentPre-Earnings Drift - careplusvn.com
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Immix (IMMX) Latest: Ends Higher by 3.80% at $13.66 in Latest Trading; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in Latest TradingScalping Stock Signals - dars.gov.et
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks
IMMX Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.18 per Share, Shares Dip 3.38%Analyst Drop Coverage - careplusvn.com
Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMMX Q1 2026 Earnings: 15.25% EPS Surprise on Narrower Loss Despite No RevenueProfit Warning Alert - vinanet.vn
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday - MarketBeat
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law - Business Wire
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immix Biopharma (IMMX) Advances 5.45% as Biotech Sentiment StrengthensBullish Sentiment - dars.gov.et
Immix Biopharma faces investigation after hirin... - Pluang
Immix Biopharma, Inc. expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Investing News Network
ImmixBio plans one-on-one investor meetings in New York Sept. 14-16 - Stock Titan
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):